I noticed my stock prediction system issued buy alerts on all 3 of these stocks...

Fast forward to today, and these are some of the best-performing stocks in the market.

Here is the truth… Despite the market dancing around all time highs… 2024 was a difficult year for the majority of traders. Sure, the market spiked 14% higher so far… But still, most traders ended up in the red. And that’s because just THREE stocks account for all of the market’s gains… The other 497 stocks basically did nothing… You can see what I mean.    Now the problem is, most folks were NOT trading these three stocks… They were focused on these 497 stocks down here…    The same stocks that spent the majority of the year trading sideways. But when I look back at my research, I noticed my stock prediction system issued buy alerts on all 3 of these stocks… For example, it said to buy NVDA in January…   It said to buy Microsoft in March…    And it said to buy Google in May.   Fast forward to today, and these are some of the best-performing stocks in the market. Which is part of the reason I’m sending this email.  This same system is lighting up on one $26 stock now… And while I can never promise future returns, or against losses, it reminds me a lot of what we saw on NVDA, MSFT and GOOGL… That’s why I posted a free session where I walk through my system, and its newest top pick as we inch closer to the elections… I also show you the steps to take to load it into your Thinkorswim account. You can watch the free session here while the replay link is still up 'Til the next trade, Lance Ippolito The profits and performance shown are not typical. We make no future earnings claims, and you may lose money. These trades expressed are from historical backtested data in order to demonstrate the potential of the system.​

Here is the truth…   Despite the market dancing around all time highs…   2024 was a difficult year for the majority of traders.   Sure, the market spiked 14% higher so far…   But still, most traders ended up in the red.   And that’s because just THREE stocks account for all of the market’s gains…   The other 497 stocks basically did nothing…   You can see what I mean.    Now the problem is, most folks were NOT trading these three stocks…   They were focused on these 497 stocks down here…    The same stocks that spent the majority of the year trading sideways.   But when I look back at my research, I noticed my stock prediction system issued buy alerts on all 3 of these stocks…   For example, it said to buy NVDA in January…   It said to buy Microsoft in March…    And it said to buy Google in May.   Fast forward to today, and these are some of the best-performing stocks in the market.   Which is part of the reason I’m sending this email.    This same system is lighting up on one $26 stock now…   And while I can never promise future returns, or against losses, it reminds me a lot of what we saw on NVDA, MSFT and GOOGL…   That’s why I posted a free session where I walk through my system, and its newest top pick as we inch closer to the elections…   I also show you the steps to take to load it into your Thinkorswim account.   You can watch the free session here while the replay link is still up   'Til the next trade,   Lance Ippolito   The profits and performance shown are not typical. We make no future earnings claims, and you may lose money. These trades expressed are from historical backtested data in order to demonstrate the potential of the system.​

ABOUT US:  We believe that the opportunity for financial literacy and freedom belongs to all people, not just those who already have years of investing experience. The TradingPub provides an array of educational services and products that will help you navigate the markets and become a better investor. Trading is made simple through our online forum full of trading techniques to give you the best tools to kick-start your investing journey. We offer collaborative webinars and training; we love to teach. No matter the opportunity, we bring together a strong community of like-minded traders to focus on analyzing market news as it’s presented each day. DISCLAIMER: FOR INFORMATION PURPOSES ONLY. The materials presented from The TradingPub LLC are for your informational purposes only. Neither The TradingPub nor its employees offer investment, legal or tax advice of any kind, and the analysis displayed with various tools does not constitute investment, legal or tax advice and should not be interpreted as such. Using the data and analysis contained in the materials for reasons other than the informational purposes intended is at the user’s own risk. DISCLAIMER: TRADE AT YOUR OWN RISK; TRADING INVOLVES RISK OF LOSS; SEEK PROFESSIONAL ADVICE. The TradingPUb is not responsible for any losses that may occur from transactions effected based upon information or analysis contained in the presented. To the extent that you make use of the concepts with the presentation material, you are solely responsible for the applicable trading or investment decision. Trading activity, including options transactions, can involve the risk of loss, so use caution when entering any option transaction. You trade at your own risk, and it is recommended you consult with a financial advisor for investment, legal or tax advice relating to options transactions. Please visit https://thetradingpub.com/terms-of-service/ for our full Terms and Conditions. This email was sent to stevenmagallanes520.nims@blogger.com by The TradingPub 101 Marketside Ave, Suite 404 PMB 318, Ponta Vedra, FL 32081, United States Unsubscribe The TradingPub Terms of Service - The TradingPub

ABOUT US:  We believe that the opportunity for financial literacy and freedom belongs to all people, not just those who already have years of investing experience. The TradingPub provides an array of educational services and products that will help you navigate the markets and become a better investor. Trading is made simple through our online forum full of trading techniques to give you the best tools to kick-start your investing journey. We offer collaborative webinars and training; we love to teach. No matter the opportunity, we bring together a strong community of like-minded traders to focus on analyzing market news as it’s presented each day.   DISCLAIMER: FOR INFORMATION PURPOSES ONLY. The materials presented from The TradingPub LLC are for your informational purposes only. Neither The TradingPub nor its employees offer investment, legal or tax advice of any kind, and the analysis displayed with various tools does not constitute investment, legal or tax advice and should not be interpreted as such. Using the data and analysis contained in the materials for reasons other than the informational purposes intended is at the user’s own risk.   DISCLAIMER: TRADE AT YOUR OWN RISK; TRADING INVOLVES RISK OF LOSS; SEEK PROFESSIONAL ADVICE. The TradingPUb is not responsible for any losses that may occur from transactions effected based upon information or analysis contained in the presented. To the extent that you make use of the concepts with the presentation material, you are solely responsible for the applicable trading or investment decision. Trading activity, including options transactions, can involve the risk of loss, so use caution when entering any option transaction. You trade at your own risk, and it is recommended you consult with a financial advisor for investment, legal or tax advice relating to options transactions.   Please visit https://thetradingpub.com/terms-of-service/ for our full Terms and Conditions.   This email was sent to stevenmagallanes520.nims@blogger.com by The TradingPub 101 Marketside Ave, Suite 404 PMB 318, Ponta Vedra, FL 32081, United States   Unsubscribe   The TradingPub Terms of Service - The TradingPub

Opinion Today: Are we thinking about obesity all wrong?

In the age of Ozempic, there is an urgent need to clarify our understanding of this illness.

View in browser|nytimes.com September 21, 2024 Daniel Forero Because of technical issues, you might have received the Opinion Today newsletter multiple times yesterday. We apologize for the error. By Julia Belluz Ms. Belluz is a health journalist based in Paris. She is co-writing a book about nutrition and health. I became interested in the science of obesity when I started reporting on bariatric surgery nearly a decade ago. It wasn't the surgery itself that captivated me; it was the fact that, at the time, altering the stomach and rerouting the intestines was far and away the most effective intervention for significant weight loss. The evidence was and is clear. And yet only about 1 percent of people who were eligible got the surgery. Instead, people mostly continued to buy into diets, exercise routines and other products of the diet culture that too often fail. There seemed to be a huge disconnect between how researchers who studied obesity thought about effective treatments and where the public turned for help. I've followed these gaps between science and public understanding in my reporting on obesity ever since, most recently turning my attention to a question that now permeates the discussion about the new class of obesity medications, the first real rivals to bariatric surgery: Does obesity constitute a disease? As I write in my guest essay for Times Opinion this week, the American Medical Association declared obesity a disease in 2013, against the advice of its own scientific council. The idea has gained more acceptance since drugs like Wegovy and Ozempic exploded in popularity. But when I dug a little, I learned that other countries haven't followed the United State — including Denmark, home to Novo Nordisk, the maker of Ozempic and Wegovy. In my essay, I explain why obesity's classification as a disease has been so controversial in both medicine and public discourse. The reasons are different but the root cause is the same. It has to do with the myth that obesity is a choice, and a surprising lack of consensus about how to properly define and diagnose it. This murkiness has arguably set health care and policy back decades. As new obesity drugs emerge, it has become only more urgent to clarify what, exactly, this illness is and who is sick. READ THE FULL ESSAY HERE Guest Essay Are We Thinking About Obesity All Wrong? Experts are rushing to redefine obesity amid soaring demand for new weight loss drugs. By Julia Belluz THE WEEK IN BIG IDEAS Kyle Johnson for The New York Times Guest Essay Alexandria Ocasio-Cortez and Tina Smith: Our Solution to the Housing Crisis Instead of treating real estate as a commodity, we can underwrite the construction of millions of permanently affordable homes and apartments. By Alexandria Ocasio-Cortez and Tina Smith Alëna Skarina Guest Essay One of the World's Biggest Health Risks Is a Philanthropic Blind Spot Money to monitor air quality in some of the most polluted places in the world can lead to cleaner air and healthier populations. By Christa Hasenkopf Ibrahim Rayintakath David Wallace-Wells When We Try to Explain the Rise of Trump, We Don't Look Back Far Enough The global war on terror changed the course of American history. So why have we forgotten about it? By David Wallace-Wells The New York Times The Ezra Klein Show Israel vs. Hamas, Hezbollah, Iran — and Itself David Remnick discusses Israel's overlapping conflicts after nearly a year of war. 1 HR 16 MIN LISTEN We hope you've enjoyed this newsletter, which is made possible through subscriber support. Subscribe to The New York Times. Games Here are today's Mini Crossword, Wordle and Spelling Bee. If you're in the mood to play more, find all our games here. Forward this newsletter to friends to share ideas and perspectives that will help inform their lives. They can sign up here. Do you have feedback? Email us at opiniontoday@nytimes.com. If you have questions about your Times account, delivery problems or other issues, visit our Help Page or contact The Times. Need help? Review our newsletter help page or contact us for assistance. You received this email because you signed up for the Opinion Today newsletter from The New York Times. To stop receiving Opinion Today, unsubscribe. To opt out of other promotional emails from The Times, including those regarding The Athletic, manage your email settings. To opt out of updates and offers sent from The Athletic, submit a request. Subscribe to The TimesGet The New York Times app Connect with us on: Change Your EmailPrivacy PolicyContact UsCalifornia Notices The New York Times Company. 620 Eighth Avenue New York, NY 10018